You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Peptide inhbitors of influenza entry-FAST TRACK

    SBC: Autoimmune Technologies, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Between 10% and 20% of the United State population suffer from seasonal influenza each year. While most individuals recover from influenza in one to two weeks, the very young, the elderly and persons with chronic medical conditions can develop post-flu pneumonia and other lethal complications. The causative agent of influenza is influenza virus, a myxovirus tha ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: NIAID

    DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed on the NIAID's Priority Pathogens and CDC's Bioterrorism Agents Lists and can cause a deadly hemorrhagic fever. No effective and safe vaccine is ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Camptothecin Analogs for Cancer Therapy

    SBC: DEKK-TEC INC            Topic: NCI

    DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic tumor tissues, characteristic of fast growing cancers that characteristically have deficient vasculature and outgrow their blood supply. Both in vitro and in vivo studies support the potential useful ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Humanized Pig Model of Cystic Fibrosis

    SBC: EXEMPLAR GENETICS, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR gene encodes a chloride channel that regulates ion flow across epithelial cell membranes. Most CF patients have a mutation that deletes phenylalanine 508 (?F508) and prevents CFTR from being properly processed and delivered to cell membra ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Porcine Model of Atherosclerosis

    SBC: EXEMPLAR GENETICS, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Atherosclerosis is the primary cause of cardiovascular disease, which is the most common cause of death in the United States. Atherosclerosis is characterized by the accumulation of lipids, cholesterol, calcium deposits, and cellular debris in vessel walls, and results in plaque formation, arterial obstruction, and diminished blood flow to organs. These plaqu ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of U1 Adaptor Technology

    SBC: INTEGRATED DNA TECHNOLOGIES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Our understanding of complex biological phenomena and disease progression has led to the realization that changes in the expression of genes underlie many of these processes. Developing reagents that can selectively alter the expression level of any desired gene has been a goal of both scientists and clinicians for years. Historically, the most common approach ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Nutritional Intervention for Age-Related Muscular Function and Strength Losses

    SBC: MTI Biotech Incorporated            Topic: NIA

    DESCRIPTION (provided by applicant): Sarcopenia, defined as age related loss of muscle mass and muscle function and strength, is very prevalent among the elderly. Sarcopenia is one of the largest public health problems facing a rapidly increasing, aging population in the United States and leads to increased incidence of falls, fractures and associated morbidities. Previous observations from our la ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Reprogrammed Cells for Differentiation into Cardiomyocytes

    SBC: NuPotential, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): NuPotential will use SBIR funds to improve a patent pending method to reprogram cells using a novel small molecule library. Reprogrammed cells generated using this improved method will be referred to as NuPiPSsm cells. In addition, NuPotential will partner with VistaGen, Inc., to differentiate NuPiPSsm cells into cardiomyocytes and assess cardiomyocyte fun ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Schweinfurthins: novel treatment for breast cancer

    SBC: TERPENOID THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. Among women with metastatic breast cancer, the 5-year survival rate is 27%. The studies proposed in this SBIR phase I application are designed to assess the feasibility of developing synthetic schwein ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Tissue and Airway Analysis for Emphysema Interventions

    SBC: VIDA DIAGNOSTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): With the considerable success of our phase 2 SBIR, we have achieved the completion of lung image analysis software that segments and thoroughly measures the lungs and their five lobes along with the airway tree. We have recently just achieved 510(k) FDA clearance for Pulmonary Workstation (PW 2.0) which now opens the door to the use of the Phase 2 software in t ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government